Shenzhen Government write-up of Ian Frazer vaccine collaboration

Source: http://www.sz.gov.cn/cn/xxgk/zfxxgj/zwdt/201809/t20180925_14114098.htm

BT Summit held 2018 International Biotherapy Summit Forum

On September 22nd, the BT Summit held the 2018 International Biotherapy Summit Forum. Ian Fraser, the inventor of the cervical cancer vaccine and academician of the Australian Academy of Sciences, revealed that he will lead the Australian team to cooperate in the development of therapeutic vaccines for cervical cancer, and strive to conduct a phase I clinical trial this year. At the forum, many Chinese and foreign biotherapeutic authorities have joined together to share the latest research results and discuss the opportunities for industrial cooperation. Liu Qingsheng, member of the Standing Committee of the Municipal Party Committee and executive deputy mayor, and Wu Yihuan, deputy mayor, attended the forum.

Liu Qingsheng said that Shenzhen is striving to build a new highland for the global biomedical industry. In recent years, the rapid development of the biomedical industry in Shenzhen has become a new driving force for economic growth. The local biomedical industry is growing at an average annual rate of 15%, biomedical engineering, gene sequencing. And bioinformatics analysis, cell therapy and other technologies rank among the world's frontiers. In the first half of this year, the growth rate of biotechnology industry ranked first in strategic emerging industries.
At the forum, Ian Fraser and Yuhui International Group formally signed a contract to serve as the group's chief scientist. At the same time, Ian Fraser signed a contract with Huihui International Group and Australian Admedus representatives as shareholders of Haohui Medical Co., which marked the official launch of HPV therapeutic vaccine research and development project in China.

Why did Ian Fraser, the father of cervical cancer vaccine, choose deep-enterprise cooperation? The company's business covers vaccine technology, biotherapy, biomedical materials, minimally invasive tumor therapy, nanomaterials and other biotechnology, providing laboratory research, clinical trials, technology conversion and production, patent applications, and drugs for biomedical related research projects. A series of industrial support and services such as declaration. Wu Yanheng, president of the group, said that he hopes to build a platform for resource sharing, technology improvement and transformation of results, and provide assistance for Shenzhen to explore new industries, research and research.

Tian Lipu, the former director of the State Intellectual Property Office, and Wang Suiming, the old leader of the city, attended the forum.